Skip to main content
BetterLife Pharma logo

BetterLife Pharma — Investor Relations & Filings

Ticker · BETR CSE Professional, scientific and technical activities
Filings indexed 282 across all filing types
Latest filing 2022-06-28 Regulatory Filings
Country CA Canada
Listing CSE BETR

About BetterLife Pharma

https://abetterlifepharma.com/

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2022-06-28 English
News release - English.pdf
Regulatory Filings
2022-06-23 English
52-109F1-AIF - Certification of filings with voluntarily filed AIF - CEO(E).pdf
Regulatory Filings
2022-06-17 English
52-109F1-AIF - Certification of filings with voluntarily filed AIF - CFO(E).pdf
Regulatory Filings
2022-06-17 English
Annual information form - English.pdf
Regulatory Filings
2022-06-17 English
News release - English.pdf
Regulatory Filings
2022-04-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.